Sorrento TherapeuticsSRNE
13F holders, Q3 2024 (September 30)4holders −1
1new positions
2sold out
$0.00avg. 13F price*
At the end of Q3 2024, 4 institutions reported holding Sorrento Therapeutics Inc. (SRNE) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Lattice Capital Management, LLC ($207), HighPoint Advisor Group LLC ($60) and Huntington National Bank ($20).
- Company
- Sorrento Therapeutics Inc.
- CUSIP
- 83587F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $60 |
| Exits | 2 | $285 |
All 13F filers, Q2 2024 → Q3 2024: 22,250 shares bought and 32,135 shares sold, net −9,885 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Lattice Capital Management, LLC | 0.00% | No change | 51,800 | $207 |
| HighPoint Advisor Group LLC | 0.00% | New | 22,250 | $60 |
| Huntington National Bank | 0.00% | No change | 5,001 | $20 |
| SlateStone Wealth, LLC | 0.00% | No change | 21,433 | $0 |
"% of holder's portfolio" is SRNE's weight in each manager's 13F, not the share of Sorrento Therapeutics Inc. the manager owns.